Denali Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Denali Therapeutics Inc.
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
The group’s gene therapy reduces saccharide levels in the rare childhood disease known as Hunter syndrome, but a confirmatory trial will be needed.
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
- Large Molecule
- Other Names / Subsidiaries
- F-star Gamma
- Incro Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.